Skip to main content
Premium Trial:

Request an Annual Quote

Affy s Q1 Sales Sink 10 Percent as Profit Dwindles; Shares Fall Below 52-Week Low

NEW YORK, April 21 (GenomeWeb News) - Affymetrix yesterday said that first-quarter sales declined more than  10 percent as overall revenue fell 2.5 percent year over year amid growing R&D expenses and shrunken profits.

 

The results caused shares in the company to plummet 15.88 percent, or $5.38, to $28.50 in early-morning trade today, below the company's 52-week low of $29.80. The company's stock has lost more than half its value since early July last year.

 

Sales for the three months ended March 31 fell to $66 million from 73.6 million year over year. Product-related revenue, however, increased 16.8 percent to $13.2 million year over year and revenue from Perlegen Sciences more than doubled to $5.3 million, Affy said. Royalties and "other" revenue" increased 18.8 percent to $1.9 million year over year.

 

Total receipts for the period declined to $86.4 million from $88.6 million in the year-ago quarter.

 

R&D spending in the quarter surged 38.2 percent to $23.5 million from $17 million year over year.

 

Profits sank to $1.8 million, or $.03 per basic share, from $16.2 million, or $.26 per basic share, one year ago.

 

Affy said it had around $104.5 million in cash and equivalents and around $150 million in short-term securities as of March 31.

 

The company on Wednesday said Sue Siegel, president since 1999, has resigned.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.